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Abstract: Cancer patients comprise a vulnerable collective exposed to numerous, 
serious risks, beyond the cancer itself. In recent years, these individuals’ prognosis 
has improved substantially thanks to several advances, such as immunotherapy, 
targeted molecular therapies, surgical techniques, or developments in support 
treatment. This coincides with the prolonged survival of oncological patients 
hospitalized in the ICU for critical complications. Thus, the time has come to revisit 
intensive care support for these patients, which poses new professional as well as 
organizational challenges. An agreement was therefore signed in 2017 between 
SEOM and SEMICYUC with the aim of improving the quality of care of cancer 
patients with critical complications. It seeks to aid in decision-making, standardize 
criteria, decrease subjectivity, generate channels of communication, and delve 
deeper into the ethical and scientific aspects of these situations. This document sets 
forth the most important reasons that have led us to undertake this initiative. 
 
Keywords: SEOM; SEMICYUC; cancer; ICU; shock; respiratory failure 
Comentado [ACB1]:  
Running head: Intensive support in cancer patients  
INTRODUCTION 
Cancer patients, even those who respond to treatment and become long-term 
survivors, are exposed to numerous potential risks, including the most obvious one: 
progression of their cancer. To name just a few of these dangers, respiratory failure 
is estimated to affect between 10-50%1; febrile neutropenia in 5-50%, with severe 
complications or acute organ failure in some 25%2; thromboembolic disease 
develops in 20% and is associated with hemodynamic instability in a high percentage 
of cases3. Putting end-of-life palliative care aside, many of these patients with severe 
complications, such as sepsis, respiratory failure, severe toxicities, etc. are cared for 
on Oncology wards.  
Recently, several observational registries have estimated a cumulative incidence of 
Intensive Care Unit (ICU) admissions of cancer patients of approximately 5-7%, 
although this figure varies considerably depending on tumor type and other 
variables4–6. To translate this into absolute terms, we must bear in mind that cancer 
is a leading cause of morbi-mortality worldwide, with approximately 14 million new 
cases per year7,8. The trend is growing and population estimates point toward a rising 
number of new cases in the coming two decades to reach 22 million diagnoses every 
year. Therefore, more and more cancer patients are expected to be eligible for ICU 
admission9. At present, roughly 15% of all ICU admissions are oncological patients 
and, according to the SEER (Surveillance, Epidemiology, and End Results) data, a 
yearly increase of 6.6% was recorded between 1993 and 200210. Although part of 
that can be attributed to the epidemiological patterns of cancer11, as oncological 
treatments become more and more efficacious and patient prognosis improves, the 
need for critical care is likely to intensify. 
 
IMPROVED PROGNOSIS FOR ONCOLOGICAL PATIENTS  
Cancer patients have typically been regarded as highly vulnerable. Nevertheless, for 
the last 15 years, population registries have consistently reported improved 
survival12,13. Beyond the contribution of early diagnosis and palliative and supportive 
care, this prolonged survival is due to a new generation of targeted cancer 
treatments.  
Since the Food and Drug Administration (FDA) approved the use of the first targeted 
drug, trastuzumab in September 199814, tens of molecules have been integrated into 
our therapeutic arsenal15. For instance, imatinib now enables more than 50% of 
patients with gastrointestinal stromal tumors (GIST), previously deemed rapidly fatal, 
to survive for more than 5 years16. The first CTLA-4-blocking antibody for the 
treatment of melanoma, ipilimumab, was approved in 2011. Since then, new 
immuno-oncology strategies have revolutionized the treatment of various neoplasms, 
including pre-treated individuals, previously considered refractory to any therapy. 
Thus, the KEYNOTE-010 trial has recently proven that pembrolizumab (anti-PD1 
antibody) could achieve long-term survival rates of 21%-25% in previously treated 
lung cancer patients, in comparison with the anecdotal survival of those who receive 
conventional chemotherapy17. In melanoma, ipilimumab, anti-PD1 antibodies, and 
anti-MEK or anti-BRAF drugs yield 12-month survival rates of some 75%, which is 
very uncommon with chemotherapy alone18. In another common tumor, colorectal 
cancer, median survival has gone from 6 to more than 30 months in recent years19, 
with the possibility of cure following metastasectomy and combined treatments20. 
Essentially all prevalent tumors have attained similar improvements in survival. 
Furthermore, the research agenda into new targets is vast and other novelties 
include poly(ADP-ribose) polymerase (PARP) inhibitors, cyclin-dependent kinases 4 
and 6 (CDK4/6) inhibitors, antiangiogenics, or multi-targeted tyrosine kinase 
inhibitors, among others.  
The benefit of these strategies surpasses that of the intrinsic effect of the drugs. The 
availability of effective therapies comprises a stimulus that opens the way to progress 
on other levels, including more ambitious indications and surgical techniques for 
primary tumors and metastases, individualized treatments, and better diagnostic 
processes and outcome evaluation.  
This is a virtuous circle, seen as a feedback process in which a beneficial event sets 
off a chain of favorable outcomes that spreads to other levels, stimulating efforts of 
other specialists, which, in turn, results in more cancer patients benefitting from 
therapies and coming back to amplify the original positive effects (Figure 1).  
Novel drugs not only lead to greater expectations, but also new challenges and 
toxicities15,21. In the previous decade, a generation of oncologists had learned that 
some of the most intense and aggressive antineoplastic strategies (e.g., taxanes for 
adjuvant use in breast cancer) were theoretically efficacious, but would only truly be 
applicable when they could properly prevent and treat the most severe complications 
and toxicities22,23. Today, it is crucial that these lessons from the past not be 
squandered; instead, we must endeavor to apply them in the new emerging scenario.  
 
CAUSE FOR ICU ADMISSION OF ONCOLOGICAL PATIENTS  
More and more of these patients are being admitted to the ICU to manage infectious 
or non-infectious complications associated with the disease itself, treatment side 
effects, or for an ailment unrelated to their cancer requiring ICU care. Shock, 
respiratory failure, neurological impairment, and acute kidney failure are the leading 
causes of ICU admissions of cancer patients24,25. Moreover, approximately 30% of all 
oncological patients (including those with hematologic cancers) who are admitted to 
the ICU present neutropenia26, traditionally believed to associate extremely high 
mortality that advised against their admission to the ICU, given its futility. Moreover, 
another growing plethora of reasons for admission is currently accepted, such as the 
management of specific syndromes (e.g., tumor lysis, airway obstruction, severe 
hydroelectrolyte imbalance, immune-mediated adverse effects, or desensitization to 
cytostatics). 
Admission is currently deemed reasonable for patients with non-small-cell lung 
cancer with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase 
(ALK) mutations who debut with respiratory failure and require mechanical ventilation 
(MV). In these conditions, tyrosine kinase inhibitors (TKI), such as erlotinib or 
crizotinib, are correlated with rapid tumor response and dramatic recovery27,28. 
Urgent chemotherapy has even been administered together with intensive support 
treatments that include MV. The need for chemotherapy for patients with recently 
diagnosed an advanced tumor should not contraindicate ICU admission; in fact, it 
may well be feasible in selected cases29. 
 
IMPROVED PROGNOSIS FOR ONCOLOGICAL PATIENTS ADMITTED TO ICU 
Advances in early diagnosis and the development of new treatments have 
significantly prolonged survival in cancer patients in the ICU. This is due to a series 
of incremental insights into the physiopathology of the diseases, particularly, 
multiorgan failure, and breakthroughs in diagnostics and treatment (Figure 2). 
Progress includes better diagnostic techniques (e.g., diagnosis of respiratory 
distress), stratification scales, sepsis and febrile neutropenia algorithms, the 
development of antifungals, or non-invasive MV30–33. The outcome of all this is that, 
one by one, results have also begun to improve for subgroups with specific 
complications, confirming general trends.  
In contrast, it has not been easy to demonstrate a general increase in survival in time 
series of patients with cancer admitted in ICUs34. There is rarely a direct answer to 
this type of question, since both complications and patients are diverse and we still 
lack data from the post-immunotherapy era and long-term outcomes, enriched with 
accurate descriptions of the oncological context34. Most of the survival data published 
in these conditions still lack all the contextualized information from an oncological 
perspective that we would like, so as to have a clear idea of what is indeed going on.  
Nevertheless, series in the 1990s reported extremely high intrahospital mortality 
rates in this population, especially in individuals with neutropenic sepsis, bone 
marrow transplant, or ventilatory failure. In recent decades, we have witnessed an 
important fall in mortality among cancer patients admitted into these units, from 80% 
(all but universal when MV was needed) to 40% (~60% when MV is required) at 
present35–40. One meta-analysis that pooled 38 studies of cancer patients 
necessitating admission to ICU examined a total of 6054 patients (2097 neutropenic). 
During the study period (2005-2015), mortality declined by 11%26. Interestingly, the 
crude mortality rate for neutropenic vs. non-neutropenic patients rose by 10%. 
However, after adjusting for confounding variables, neutropenia did not significantly 
impact mortality. In fact, it is currently thought that cancer patients benefit from ICU 
admission just as much as individuals with other underlying medical conditions, such 
as cirrhosis of the liver or chronic heart failure40. 
On the other hand, MV was previously considered to be futile, but given the improved 
survival rate achieved in the last decade thanks to positive pressure ventilation (PPV) 
41,42, current thought is that invasive or non-invasive PPV should be used in cancer 
patients with acute respiratory failure receiving curative or palliative treatment, with 
good functional status, and consistent with patients’ wishes, since hospital survival is 
60% when it is implemented. A recent study conducted in England, Wales, and 
Northern Ireland of more than 90,000 patients with solid tumors admitted to intensive 
care between 1997 and 2013 revealed greater survival between 2009-2013 as 
opposed to the previous period and a mortality rate of only 26%43. 
 
EARLY TREATMENT OF THE CRITICAL CANCER PATIENT 
Early admission of critical oncological patients improves their prognosis and has 
been identified as an independent factor associated with higher survival rates44,45. 
We know that many of the techniques applied in the ICU achieve better outcomes 
when initiated early and that delaying treatments entails a worse prognosis for all 
patients46,47. This is evident in the case of sepsis that cancer patients often develop, 
as well as in cases of acute respiratory failure that benefit from early ventilatory 
support39,48. Early administration of non-invasive respiratory support (non-invasive 
MV or high-flow nasal oxygen) has proven to be efficacious in these patients in 
preventing the need for invasive MV and lower mortality in cancer patients with 
respiratory failure49,50. 
 
SHARED DECISION-MAKING FOR CANCER PATIENT ADMISSION TO 
INTENSIVE CARE 
We are currently seeing a paradigm shift as regards treatment approach and 
admission of patients with active oncological disease to ICU42,51 owing to different 
circumstances, such as a change in prognosis for cancer in recent years even after 
being admitted to an ICU 52,53, improved quality of life after receiving treatment, and 
the evolution of monitoring systems and treatment in Intensive Care, enabling less 
invasive and aggressive support, adapting treatment to the patient, as well as 
possibly to a change in thinking about treatment objectives in caring for critical 
patients54.  
In 2011, an international consensus was published on ICU admission criteria in 
patients with cancer42. The consensus established different groups of possible 
alternatives and treatment steps, ranging from admission for the use of all treatment 
measures available to different treatment options to suit each patient’s true aims, 
including alternatives for treatments that can potentially cause immediate 
complications and alternatives for palliative treatment.  
In general, we can state that at present, admission of this group of patients to the 
ICU would be justified in four circumstances: 
1) The reason for ICU admission must be reversible, regardless of the cancer. 
2) The prognosis for the cancer itself justifies applying potentially aggressive 
treatments, given the expectation of being able to maintain adequate subsequent 
quality of life.  
3) The patient, or their legal representatives when necessary, does not refuse 
treatment in the ICU.  
4) The patient has good quality of life prior to the complication, with feasible 
cancer treatment options and reasonable expectation for survival. 
 
Be that as it may, we believe that at present, these patients can clearly benefit from 
the existence of a closer relationship between Oncology and Intensive Care 
Medicine. This would entail setting up top quality, structured consultations between 
both services. The prognosis for each patient must be adequately and accurately 
established, planning ahead (together with the patient and their family) for possible 
complications, creating plans for future treatment, and contemplating early admission 
or adequate treatment for organ dysfunction, as well as palliative treatment plans. 
The ICU trial admission policy, with rapid transition to Palliative Care if evolution is 
unfavorable, is a particularly appropriate admission model for some patients with 
advanced cancer55. 
Progress undoubtedly implies new responsibilities for all professionals involved in 
treating cancer; however, they also call for important organizational repercussions for 
each center’s daily activity. Additionally, in terms of pharmacoeconomics, the only 
way to amortize the huge investments of resources in anti-cancer treatments is 
through proper, efficient, and rational decision-making that also factors in support for 
toxicities and complications. 
One possibility that has grown in recent years is multi-professional, inter-specialty 
collaboration in managing these individuals in the initial stages on regular wards, with 
follow-up by means of systems that alert of both clinical and analytical decline, 
allowing us to get a jump on complications50,56.  
We must all be aware of the fact that we, as professionals as well as all parties 
concerned, have cognitive biases that will definitely affect decision-making. Being 
cognizant of the impact of irrational decision-making on such a vulnerable group of 
patients is the only way to find a truly better alternative in each case. Therefore and 
insofar as possible, decisions should be protocolized ahead of time, by means of 
practicable algorithms accepted by all the hospital teams; goals should be discussed 
ahead of time with the patients whenever possible, taking into account the families’ 
wishes and values in other situations of uncertainty. 
Given that intensive care physicians do not participate in the patient’s overall 
treatment strategy, they will only be aware of the tip of the iceberg; i.e., a specific 
critical condition. In contrast, the oncologist, lacking sufficient objective elements, 
confronts a highly subjective decision. Thus, a 15% discrepancy has been reported 
between oncologists/hematologists as regards the suitability of transferring a patient 
to the ICU25.  
Furthermore, the general trend is to look for strategies to lessen the negative impact 
of ICU admission in this vulnerable population, thereby enabling more patients to 
benefit from this kind of care. These efforts include open ICU policies, preventive ICU 
admissions, and the use of critical treatments in controlled conditions outside of the 
ICU42,55. Management is probably clear for the long-term survivor, complications from 
adjuvant treatment, or sustained response to immunotherapy over time. However, it 
is less obvious how these strategies should be individually transmitted to other cases 
(e.g., unevaluated response) and will probably continue to be open to debate.  
A new clinical research agenda has therefore been opened that aspires to gain 
greater insight into the conditions that lead to full recovery and continuation of anti-
neoplastic therapy, subjective endpoints, such as health-related quality of life or 
symptomatic control, the application of shared decision-making models, and 
admission policies, in light of new options, as well as investigating the effect of new 
care modalities and critical management outside of the ICU in a contextualized 
manner57. 
 
THE ROLE OF THE ONCOLOGIST WHEN THE PATIENT IS ADMITTED TO THE 
ICU 
In the age of immunotherapy, determining who is eligible for full code admission 
(decision to administer all advanced life support techniques if necessary, including 
cardiopulmonary resuscitation maneuvers and MV), ICU trial (full code for 3-4 days 
followed by reevaluation of the level of support going forward), or non-admission to 
ICU can be extremely complex, given the uncertainty surrounding the patient’s 
possibility of becoming a long-term survivor. The oncologist’s fundamental role is to 
contribute their prior knowledge about the patient, prognostic factors, and 
possibilities for recovery 45,58. Cancer is not a single clinical and molecular reality. At 
present, the mere label of cancer does not suffice and calls for greater knowledge 
about its molecular alterations, stage, available treatment options, etc. However, it is 
worth mentioning that recent developments in treating cancer not only fail to 
ameliorate uncertainty, but instead, actually increase it, given the impossibility of 
knowing ahead of time which patient is most likely to become a long-term survivor59. 
Once the patient has been admitted to the ICU, the oncologist’s role must be to aid in 
the prevention, diagnosis, and management of specific complications (e.g., drug-
induced toxicity, neutropenia…). During follow-up, the oncologist must collaborate 
with the intensive care physician in decision-making (e.g., initiation of aggressive 
support measures, transition to Palliative Care, etc.). 
 
SEOM-SEMICYUC COLLABORATION 
The time has come to revisit the ICU admission policy of some of these patients to 
optimize their support treatment. As a result of these reflections between 
professionals of both societies, in June 2017 the first SEOM-SEMICYUC Framework 
Collaboration Agreement was signed, with the aim of improving the quality of care of 
cancer patients with critical complications. This agreement is in line with recent work 
and consensus with institutions around the world57. Among the most salient aspects 
of this agreement are to: 
1. Contribute to improving care for cancer patients with critical complications for 
whom intensification of support treatment is indicated. 
2. Aid in shared decision-making between Oncology and Intensive Care Medicine, 
by jointly drafting Evidence-Based Clinical Practice Guidelines, setting forth the 
main indications for ICU admission and treatment of cancer patients, addressing 
their differences and special characteristics with respect to other patients. 
3. Contribute to standardizing care for these patients, reducing unjustified variability, 
subjectivity, and bias in decision-making. 
4. Generate channels of communication to boost information exchange and 
dialogue between both specialties, with the aim of delving deeper into the 
scientific and ethical aspects of decision-making. 
5. Contribute to creating working groups dedicated to specific treatment aspects 
(infections in immunodepressed individuals, non-invasive MV in cancer patients, 
etc.). 
6. Develop joint clinical registries and clinical or basic research projects that enable 
us to better understand prognostic factors of critical oncological patients and 
generating evidence of the best diagnostic and therapeutic approaches. 
 
CONCLUSION  
Oncological patients’ survival has improved markedly in recent years, coinciding with 
a decrease in intrahospital mortality among these individuals. With this comes the 
need for both oncologists and intensive care physicians to change their thinking once 
and for all about ICU admission for selected patients. Quality consultation among 
professionals must be fostered to decide on the best attitude to adopt in each case 
without bias. All patients with possibilities of being cured should be routinely admitted 
to the ICU (e.g., adjuvant or neoadjuvant therapies). Likewise, patients with 
chemosensitive tumors, mutations predictive of response with targeted therapies, 
possibilities of long-term tumor control with immunotherapy, and other specific 
situations should be deemed eligible for ICU admission, in a concerted manner, on 
the basis of their distinct characteristics. 
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Figure 2.   Summary of progress in intensive management of cancer patients  
 
 
